Our Team

PUBLICATIONS >
 

2009-2011
Postdoctoral studies
CRCHUM, Hôpital Notre-Dame, Institut du Cancer de Montreal
Departement de Biologie moléculaire, Université de Montreal
Supervisor : Dr Richard Bertrand

2005-2008
Postdoctoral studies
Department of Radiation Oncology, School of Medicine
Stanford, University
Supervisor: Dr Amato J. Giaccia

1999-2004
Doctorate in biochemistry (PhD)
Laboratoire de Médecine Moléculaire,
Université du Québec à Montréal (UQAM),
Supervisor: Dr Richard Béliveau

1997-1999
Master in chemistry (Biochemistry) (M.Sc)
Université du Québec à Montréal
Supervisor: Dr Diana A. Averill-Bates

1994-1997
Bachelor in biochemistry (B.Sc)
Université du Québec à Montréal


Funding :

2014-2019

Canadian Institutes for Health Research

2012-2014
Cancer Research Society

2012-2015
KRESCENT New Investigator

2012-2015
NB Health Research Foundation

2012-2015
NB Innovation Foundation

Dr Sandra Turcotte is Assistant Professor at the Université de Moncton and Researcher in Residency at the Atlantic Cancer Research Institute. She completed her PhD in Biochemistry at the Université du Québec à Montréal and Post-doctoral Fellowships at Stanford University in California and at the CRCHUM in Montreal. Dr Turcotte joined the Université de Moncton and ACRI in 2011 with a Research Chair from the Canadian Cancer Society New Brunswick. She is also recipient of a KRESCENT (Kidney Research Scientist Core Education and National Training program) New Investigator award (2012-2015).

Dr Turcotte is member of professional organization such as the Canadian Society of Nephrology and different associations and network such as the Beatrice Hunter Cancer Research Institute and the Kidney Cancer Research Network of Canada. She is also active in grant and scientific journal reviews, and teaching activities. She developed collaborations with national provincial researchers including some of her colleagues at the Université and ACRI.


Research Interests:

Kidney Cancer, clear cell Renal Cell Carinoma
Targeted therapy, synthetic lethality
Autophagy, lysosome
Translational research

Dr Turcotte's research interests focus on kidney cancer to develop targeted therapy based on synthetic lethality. Her studies identify a small molecule that target the loss of the von Hippel-Lindau (VHL) tumor suppressor gene by inducing autophagy. Her laboratory uses a variety of methods from genomic to metabolomic to study the role of autophagy in renal cancer cells. This work aim to transfer knowledge form laboratory bench to bedside to treat patient with kidney cancer.


Twitter

Archived Articles

btn campain EN
Atlantic Cancer Research Institute 
Pavillon Hôtel-Dieu
35, Providence Street
Moncton, NB E1C 8X3 Canada

info@canceratl.ca
Tel.: 506-862-7512
Fax.: 506-862-7571

Annual Report 2017 Cover
Our annual report
Download PDF bullet blanc

The Atlantic Cancer Research Institute

 (ACRI) is a non-profit organization founded in late 1998 and housed at the Dr. Georges-L.-Dumont University Hospital Centre in Moncton. Thanks to its unique expertise, ACRI has become a true centre of excellence in cancer research.

Our Partners

logo excipio logo chudumont logo soricimedlogo neplogo ccslogo umonctonlogo unblogo vitalitelogo conceptiaCRS logoNBHRF logoMerck Logo.svg